Combination vaccines: design strategies and future trends

References

• Del Giudice G. Vaccination strategies: an overview. Vaccine21(Suppl.), S83–S88 (2003).
   Google Scholar
• Clements C, Wesselingh S. Vaccine presentations and delivery technologies - what does the future hold? Expert Rev. Vaccines 4(3), 281–287 (2005).
   PubMed Web of Science ®Google Scholar
• Bar-Zeev N, Buttery J. Combination conjugate vaccines. Expert Opin. Drug. Saf.5(3), 351–360 (2006).
   PubMed Web of Science ®Google Scholar
• HSS, F.U.D.o. Guidance for industry for the evaluation of combination vaccines for prevention of diseases: production, testing and clinical studies. Rockville, MD, USA (1997).
   Google Scholar
• van den Dobbelsteen G, van Dijken H, Pillai S, van Alphena L. Immunogenicity of a combination vaccine containing pneumococcal conjugates and meningococcal PorA OMVs. Vaccine24 (2006) (Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• CDC. Recommended childhood immunization schedule: United States. MMWR (Recommendations & Reports)51, 31–33 (2002).
   Google Scholar
• Yeh S, Ward J. Strategies for development of combination vaccines. Pediatr. Infect. Dis. J.20(Suppl. 11), S5–S9 (2001).
   Google Scholar
• Pediatrics , A.A.o. Combination vaccines for childhood immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP) and the American Academy of Family Physicians (AAFP). Pediatrics103, 1064–1077 (1999).
   PubMed Web of Science ®Google Scholar
• Rennels M. Combination vaccines. Pediatr. Infect. Dis. J.21, 255–257 (2002).
   PubMed Web of Science ®Google Scholar
• Kane A, Lloyd J, Zaffran M, Simonsen L, Kane M. Transmission of hepatitis B, C and human immunodeficiency virus through unsafe injections in the developing world: model-based regional estimates. Bull. World Health Organ.77, 801–807 (1999).
   PubMed Web of Science ®Google Scholar
• Hutin Y, Chen R. Injection safety: a global challenge. Bull. World Health Organ.77, 787–788 (1999).
   PubMed Web of Science ®Google Scholar
• King G, Hadler S. Simultaneous administration of childhood vaccines: an important public health policy that is safe and efficacious. Pediatr. Infect. Dis. J.13, 394–407 (1994).
   PubMed Web of Science ®Google Scholar
• Ball L, Falk L, Horne A, Finn T. Evaluating the immune response to combination vaccines. Clin. Infect. Dis.33(Suppl. 4), S299–S305 (2001).
   PubMed Web of Science ®Google Scholar
• Avery O, Goebel W. Chemo-immunological studies on conjugated carbohydrate-protein. Part II. Immunological specificity of synthetic sugar-protein antigens. J. Exp. Med.50, 533–550 (1929).
   PubMedGoogle Scholar
• Tacken P, Torensma R, Figdor C. Targeting antigens to dendritic cellls in vivo. Immunobiology211, 599–608 (2006).
   PubMed Web of Science ®Google Scholar
• Burns S, Thrasher AJ. Dendritic cells: the bare bones of immunity. Curr. Biol.14, R965–R967 (2004).
   PubMed Web of Science ®Google Scholar
• Kaisho T, Akira S. Regulation of dendritic cell function through Toll-like receptors. Curr. Mol. Med.3(4), 373–385 (2003).
   PubMed Web of Science ®Google Scholar
• Schutze M, Leclerc C, Jolivet M, Audibert F, Chedid L. Carrier-induced epitope suppression, a major issue for future synthetic vaccines. J. Immunol.135(4), 2319–2322 (1985).
   PubMed Web of Science ®Google Scholar
• Dagan R, Eskola J, Leclerc C, Leroy O. Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants. Infect. Immun.66(5), 2093–2098 (1998).
   PubMed Web of Science ®Google Scholar
• Daum RS, Zenko CE, Given GZ, Ballanco GA, Parikh H, Germino K. Magnitude of interference after dipththeria-tetanus toxoids-acellular pertussis/Hemophilus influenzae type b capsular polysaccharide-tetanus vaccination is related to the number of doses administered. J. Infect. Dis.184(10), 1293–1299 (2001).
   PubMed Web of Science ®Google Scholar
• Fattom A, Cho YH, Chu C, Fuller S, Fries L, Naso R. Epitope overload at the site of injection may result in suppression of hte immune response to combined capsular polysaccharide conjugate vaccines. Vaccine17(2), 126–133 (1999).
   PubMed Web of Science ®Google Scholar
• Williams J, Fox-Leyva L, Christensen C et al. Hepatitis A vaccine administration: comparison between jet-injector and needle injection. Vaccine18(18), 1939–1943 (2000).
   PubMed Web of Science ®Google Scholar
• Aguado T, Jodar L, Lloyd J, Lambert P. Injectable solid vaccines: role in future immunization? Bull. World Health Organ. Drug Inf. 12, 68–69 (1998).
   Google Scholar
• WHO. Vaccines and biologicals annual report. WHO, Geneva WHO/V&B/99.01 (1998).
   Google Scholar
• Turner MS, Giffard PM. Expression of Chlamydia psittaci and human immunodeficiency virus-derived antigens on the cell surface of Lactobacillus fermentum BR11 as fusion to bspA. Infect. Immun.67(10), 5486–5489 (1999).
   PubMed Web of Science ®Google Scholar
• Gentschev I, Dietrich G, Spreng S et al. Delivery of protein antigens and DNA by virulence-attenuated strains of Salmonella typhimurium and Listeria monocytogenes. J. Biotechnol.83(1–2), 19–26 (2000).
   PubMed Web of Science ®Google Scholar
• Eko FO, Witte A, Huter V et al. New strategies for combination vaccines based on the extended recombinant bacterial ghost system. Vaccine17, 1643–1649 (1999).
   PubMed Web of Science ®Google Scholar
• Igietseme JU, Black CM, Caldwell HD. Chlamydia vaccine: strategies and status. BioDrugs16(1), 19–35 (2002).
   PubMed Web of Science ®Google Scholar
• McMillan L, He Q, Ifere G et al. A recombinant multivalent combination vaccine protects against Chlamydia and genital herpes. FEMS Immunol. Med. Microbiol. (2006) (Epub ahead of print).
   Google Scholar
• Manickan E, Karem KL, Rouse BT. DNA vaccines: a modern gimmick or a boon to vaccinology. Crit. Rev. Immunol.17, 139–154 (1997).
   PubMed Web of Science ®Google Scholar
• Seder RA, Gurunathan S. DNA vaccine – designer vaccines for the 21st century. N. Engl. J. Med.341(4), 277–278 (1999).
   PubMed Web of Science ®Google Scholar
• liu MA, Hilleman MR , Kurth R. DNA vaccines: a new era in vaccinology. Ann. NY Acad. Sci. (1995).
   Google Scholar
• Iwasaki A, Stiernholm BJ, Chan AK, Berinstein NL , Barber BH. Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines. J. Immunol.158(10), 4591–4601 (1997).
   PubMed Web of Science ®Google Scholar
• Gurunathan S, Irvine KR, Wu CY et al. CD40 ligand/trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infectious and tumor challenge. J. Immunol.161(9), 4563–4571 (1998).
   PubMed Web of Science ®Google Scholar
• Lu H, Xing Z Brunham RC. GM-CSF transgene-based adjuvant allows the establishment of protective mucosal immunity following vaccination with inactivated Chlamydia trachomatis. J. Immunol.169(11), 6324–6331 (2002).
   PubMed Web of Science ®Google Scholar
• Murdin AD, Dunn P, Sodoyer R et al. Use of a mouse lung challenge model to identify antigens protective against Chlamydia pneumoniae lung infection. J. Infect. Dis.181(Suppl. 3), S544–S551 (2000).
   PubMed Web of Science ®Google Scholar
• Babiuk LA, Tikoo SK. Adenoviruses as vectors for delivering vaccines to mucosal surfaces. J. Biotechnol.83(1–2), 105–113 (2000).
   PubMed Web of Science ®Google Scholar
• Hewson R. RNA viruses: emerging vectors for vaccination and gene therapy. Mol. Med. Today6(1), 28–35 (2000).
   PubMedGoogle Scholar
• Bennink JR, Yewdell JW. Recombinant vaccinia viruses as vectors for studying T lymphocyte specificity and function. Curr. Top. Microbiol. Immunol.163, 153–184 (1990).
   PubMed Web of Science ®Google Scholar
• Palese P, Zheng H, Engelhardt OG, Pleschka S, Garcia-Sastre A. Negative-strand RNA viruses: genetic engineering and applications. Proc. Natl Acad. Sci. USA93(21), 11354–11358 (1996).
   PubMed Web of Science ®Google Scholar
• Igietseme JU, He Q, Eko FO et al. Development of vaccines to prevent chlamydial STDs. Mucosal Immunol. Update13(4), 12–17 (2005).
   Google Scholar
• Nakaya T, Cros J, Park M et al. Recombinant Newcastle disease virus as a vaccine vector. J .Virol.75(23), 11868–11873 (2001).
   PubMed Web of Science ®Google Scholar
• Martinez-Sobrido L, Gitiban N, Fernandez-Sesma A et al. Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector. J .Virol.80(3), 1130–1139 (2006).
   PubMed Web of Science ®Google Scholar
• Schlesinger S, Dubensky TW. Alphavirus vectors for gene expression and vaccine. Curr. Opin. Biotechnol.10, 434–439 (1999).
   PubMed Web of Science ®Google Scholar
• Oliveira GA, Wetzel K, Calvo-Calle JM et al. Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a Phase I trial. Infect. Immun.73(6), 3587–3597 (2005).
   PubMed Web of Science ®Google Scholar
• Schodel F, Peterson D, Milich D. Hepatitis B virus core and e antigen: immune recognition and use as a vaccine carrier moiety. Intervirology39(1–2), 104–110 (1996).
   PubMed Web of Science ®Google Scholar
• Milich DR, Hughes J, Jones J, Sallberg M, Phillips TR. Conversion of poorly immunogenic malaria repeat sequences into a highly immunogenic vaccine candidate. Vaccine20(5–6), 771–788 (2001).
   PubMed Web of Science ®Google Scholar
• Stanley MA. Human papillomavirus vaccines. Rev. Med. Virol.16(3), 139–149 (2006).
   PubMed Web of Science ®Google Scholar
• Pattenden LK, Middelberg AP, Niebert M, Lipin DI. Towards the preparative and large-scale precision manufacture of virus-like particles. Trends Biotechnol.23(10), 523–529 (2005).
   PubMed Web of Science ®Google Scholar
• Saito H, Frleta D, Dubsky P, Palucka A. Dendritic cell-based vaccination against cancer. Hematol. Oncol. Clin. North. Am.20(3), 689–710 (2006).
   PubMed Web of Science ®Google Scholar
• Oelke M, Krueger C, Schneck J. Technological advances in adoptive immunotherapy. Drugs Today41(1), 13–21 (2005).
   PubMed Web of Science ®Google Scholar
• Yannelli J, Wroblewski J. On the road to a tumor cell vaccine: 20 years of cellular immunotherapy. Vaccine23(1), 97–113 (2004).
   PubMed Web of Science ®Google Scholar
• Colaco CA. Why are dendritic cells central to cancer immunotherapy? Mol. Med. Today5(1), 14–17 (1999).
   PubMedGoogle Scholar
• Igietseme JU, Ananaba GA, Bolier J et al. Suppression of endogenous IL-10 gene expression in dendritic cells enhances antigen presentation for enhanced specific Th1 induction: potential for cellular vaccine development. J. Immunol.164(4), 4212–4219 (2000).
   PubMed Web of Science ®Google Scholar
• Hoffman DM, Gitlitz BJ, Belldegrun A, Figlin RA. Adoptive cellular therapy. Semin. Oncol.27(2), 221–233 (2000).
   PubMed Web of Science ®Google Scholar
• Hajek R, Butch AW. Dendritic cell biology and the application of dendritic cells to immunotherapy of multiple myeloma. Med. Oncol.17(1), 2–15 (2000).
   PubMed Web of Science ®Google Scholar
• Citterio S, Rescigno M, Foti M et al. Dendritic cells as natural adjuvants. Methods19(1), 142–147 (1999).
   PubMed Web of Science ®Google Scholar
• Moore T, Ekworomadu C, Eko F et al. Fc receptor-mediated antibody regulation of T cell immunity against intracellular pathogens. J. Infect. Dis.188(4), 617–624 (2003).
   PubMed Web of Science ®Google Scholar
• Heijnen IAFM, van Vugt MJ, Fanger NA et al. Antigen targeting to myeloid-specific human FcγRI/CD64 triggers enhanced antibody responses in transgenic mice. J. Clin. Invest.97(2), 331–338 (1996).
   PubMed Web of Science ®Google Scholar
• Gosselin EJ, Wardwell K, Gosselin DR, Alter N, Fisher JL, Guyre PM. Enhanced antigen presentation using human Fcγ receptor (monocyte/macrophage)-specific immunogens. J. Immunol.149, 3477–3481 (1992).
   PubMed Web of Science ®Google Scholar
• Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potential and effector functions. Nature401, 708–712 (1999).
   PubMed Web of Science ®Google Scholar
• Messi M, Giacchetto I, Nagata K, Lanzavecchia A, Natoli G, Sallusto F. Memory and flexibility of cytokine gene expression as separable properties of human Th1 and Th2 lymphocytes. Nature Immunol.4, 78–86 (2003).
   PubMed Web of Science ®Google Scholar
• Schneider H, Downey J, Smith A et al. Reversal of the TCR stop signal by CTLA-4. Science313(5795), 1972–1975 (2006).
   PubMed Web of Science ®Google Scholar
• Thompson RH, Allison J, Kwon E. Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer. Urol. Oncol.24(5), 442–447 (2006).
   PubMed Web of Science ®Google Scholar